SHP Wealth Management’s Editas Medicine EDIT Stock Holding History

SHP Wealth Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$222	Hold	90	–	–	﹤0.01%	1723
2025 Q4	$184	Buy	+90	New	+$260	﹤0.01%	1471

Other funds holding EDIT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SHP Wealth Management's EDIT Position: Q1 2026 in Review

SHP Wealth Management held its Editas Medicine (EDIT) position steady in Q1 2026 at 90 shares worth $222. The position accounts for ﹤0.01% of the portfolio, ranked #1723.

SHP Wealth Management first reported a position in EDIT in Q4 2025 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold EDIT as of Q1 2026.

SHP Wealth Management held 90 shares of Editas Medicine worth $222 as of Q1 2026.
SHP Wealth Management left its Editas Medicine share count unchanged in Q1 2026.
Editas Medicine made up ﹤0.01% of SHP Wealth Management's portfolio in Q1 2026, its #1723 holding.
SHP Wealth Management first reported a position in Editas Medicine in Q4 2025 and has held it in 2 quarters since.
208 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.